Verapamil and Drug Sensitivity in Bone Marrow
Author Information
Author(s): M.A. Smith, S. Merry, J.G. Smith, S.B. Kaye
Primary Institution: University of Glasgow
Hypothesis
Does verapamil enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16?
Conclusion
Verapamil at clinically relevant doses does not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.
Supporting Evidence
- Verapamil did not reduce colony number by more than 10% compared to solvent controls.
- The mean reduction in colony number was 56% for adriamycin and 40% for VP16.
- At clinically relevant doses, verapamil had little effect on drug sensitivity.
Takeaway
The study found that verapamil, a drug that might help cancer treatments, doesn't make bone marrow cells more sensitive to certain chemotherapy drugs at the doses used in patients.
Methodology
A clonogenic assay was used to study the effect of verapamil on the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.
Limitations
Further studies are required to confirm the findings and explore the effects of different concentrations of verapamil.
Participant Demographics
Patients with iron or B12/folate deficiency.
Want to read the original?
Access the complete publication on the publisher's website